GlassScriptPhysician profile
Gregory C Maidoh
NPI 1255498754
$4,978.81
in general payments reported to CMS, 2019-2025
23 companies · $970 in 2025
The $970 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $436 · 2021: $590 · 2022: $903 · 2023: $905 · 2024: $937 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,060.18 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $571.98 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $570.31 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $556.18 | 2020-2025 | Acthar |
| Vifor Pharma, INC. | $491.14 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $398.71 | 2019-2023 | Farxiga |
| Akebia Therapeutics INC | $326.53 | 2019-2022 | |
| Travere Therapeutics, INC. | $270.86 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $95.03 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.91 | 2021-2025 | Jardiance |
| Cormedix INC. | $80.85 | 2024 | Defencath |
| Novartis Pharmaceuticals Corporation | $75.31 | 2021-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.52 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $48.07 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $46.40 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $44.19 | 2019 | |
| Amgen INC. | $39.04 | 2020-2022 | |
| Novo Nordisk INC | $37.97 | 2025 | Wegovy, Ozempic |
| Horizon Therapeutics Plc | $30.77 | 2023 | Krystexxa |
| Ascendis Pharma Endocrinology INC | $23.76 | 2024 | |
| Ani Pharmaceuticals, INC. | $21.68 | 2024 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $18.40 | 2021 | |
| Daiichi Sankyo INC. | $18.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Maidoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.